Day: January 12, 2026

Kfar Saba, Israel, Jan. 12, 2026 (GLOBE NEWSWIRE) — ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “company” or “ParaZero”), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, today reflects on a transformative 2025 for its DropAir™ Precision Airdrop System – turning battlefield lessons from recent wars into validated, life-saving technology now expanding to civilian, medical, and humanitarian markets worldwide. In 2025, ParaZero achieved a series of significant milestones that positioned DropAir as a leading solution for precise, no-landing deliveries in high-risk environments:February 2025: Successfully transitioned to Phase II of the DropAir project with the Israeli Ministry of Defense following positive Phase I results, advancing development...

WAYNE, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has initiated a placebo-controlled Phase 1b proof-of-concept (POC) trial in atopic dermatitis (AD) for ATI-052, the Company’s potential best-in-class investigational bispecific anti-TSLP/IL-4Rα antibody. “We are experiencing strong momentum in the ATI-052 clinical development program including the recent positive Phase 1a interim results which demonstrated a strong safety and tolerability profile, extended pharmacokinetics, and concentration-dependent pharmacodynamics even at the lowest dose,” said Dr. Jesse Hall, Chief Medical Officer of Aclaris. “Further to this, we are excited to announce the...

Topline data from CHAPTER-3, a pivotal study of deucrictibant for prophylactic treatment of HAE attacks, anticipated in 3Q2026 Preparation of NDA dossier of deucrictibant for on-demand treatment of HAE attacks ongoing; timeline remains on-track for filing in 1H2026 Recruitment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks Estimated cash runway into 1H2027ZUG, Switzerland, Jan. 12, 2026 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today outlined its strategic priorities for 2026. “The...

For full year 2025, total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS expected to be within or above guidance ranges of $854 million to $873 million, $221 million to $228 million and $7.37 to $7.64, respectively Rare Disease business delivered exceptional growth with full year 2025 Purified Cortrophin® Gel net revenues of $347.8 million, up 76% year-over-year, and ILUVIEN and YUTIQ net revenues of $74.9 million, based on preliminary, unaudited results Provides full year 2026 financial guidance, which includes:Total net revenues of $1,055 million to $1,115 million Cortrophin Gel net revenues of $540 million to $575 million Adjusted non-GAAP EBITDA of $275 million to $290 million Rare Disease business to represent approximately 60% of total net revenuesAnnounces ~90-person expansion of Rare Disease organization...

2026 poised to be a catalyst-rich year for BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and mRNA immunotherapies Expected 2026 oncology milestones include seven late-stage data readouts and to have 15 Phase 3 clinical trials ongoing by year end Additional late-stage trial readouts through 2030+ set to create multiple launch opportunities across tumor types, building BioNTech into a multi-product oncology company Financial strength with €17.2 billion in cash and cash equivalents plus security investments1, COVID-19 vaccine revenue stream, disciplined R&D spend, and strategic partnerships will continue to enable sustainable innovation Presentation and webcast at the 44th Annual J.P. Morgan Healthcare Conference from 2:15 – 2:55 pm PT / 11:15 – 11:55 pm CET on...

Inspire Announces Appointment of Matt Osberg as Executive Vice President and Chief Financial Officer Joining the Company in the First Quarter of 2026 MINNEAPOLIS, Jan. 12, 2026 (GLOBE NEWSWIRE) — Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”, or the “Company”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced certain preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025, and provided its initial full year 2026 revenue guidance. Further, the Company announced the appointment of Matt Osberg as Executive Vice President and Chief Financial Officer. Preliminary, Unaudited Fourth Quarter and Full Year 2025 RevenueRevenue for the fourth quarter of 2025 is anticipated...

TORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) — DPM Metals Inc. (TSX: DPM, ASX: DPM) (ARBN: 689370894) (“DPM” or “the Company”) announces that the Company has filed a technical report for its Čoka Rakita gold project in Serbia (the “Report”). The purpose of the Report is to support the Mineral Resource and Mineral Reserve estimate and feasibility study (“FS”) for Čoka Rakita, as previously disclosed in the Company’s news release dated November 26, 2025. The Report has been prepared pursuant to the Canadian Securities Administrator’s National Instrument 43-101 – Standards of Disclosure for Mineral Projects. The Report and the November 26, 2025 news release are both available for review on SEDAR+ (www.sedarplus.ca) and on the Company’s website (www.dpmmetals.com). Readers are encouraged to refer to the risks, assumptions and key parameters...

TORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) — DPM Metals Inc. (TSX: DPM, ASX: DPM) (ARBN: 689370894) (“DPM” or “the Company”) announced preliminary production results for the three and twelve months ended December 31, 2025. “We ended 2025 on a very strong note, with Ada Tepe and Chelopech delivering the highest quarterly production of the year,” said David Rae, President and Chief Executive Officer of DPM Metals. “I’m proud to report that 2025 marks the eleventh consecutive year we have achieved our gold production guidance, a remarkable milestone and a testament to our operating strengths.” “We are very pleased with the progress we are making at Vareš. We are on target to achieve an 850,000 tonne per year operating rate by the end of 2026, and we are continuing to advance training and improve development rates to accelerate precious...

BROOKFIELD NEWS, Jan. 12, 2026 (GLOBE NEWSWIRE) — Brookfield Corporation (NYSE: BN, TSX: BN) will host its fourth quarter 2025 conference call and webcast on Thursday, February 12, 2026 at 10:00am (ET). Results will be released that morning at approximately 7:00am (ET) and available on our website at https://bn.brookfield.com/news-events/press-releases. Participants can join by conference call or webcast: Conference CallPlease pre-register by conference call:https://register-conf.media-server.com/register/BI05aa338a69c24655a385c99f447d7557 Upon registering, you will be emailed a dial-in number, and unique PIN. This process will bypass the operator and avoid the queue.WebcastPlease join and register by webcast: https://edge.media-server.com/mmc/p/gk98ibhd Replay of the event is available on the above webcast link for 90 days.About...